Durability: ABC ® Platform-based medicines are designed for longer ocular durability Increases as molecular weight increases for intravitreal biologics Achieved with lower molecular-weight intravitreal biologics Conjugated Portion of ABC ® Platform-based medicines* *Kodiak’s ABC platform-based medicines Zenkuda and KSI-501 combine unconjugated and conjugated protein in a single biologic Zenkuda 1000 kDa ABC ® Platform-based medicines have a high molecular weight which increases their ocular half-life compared to today’s intravitreal biologics 950 kDa KSI-501 Immediacy Durability 12